Key Highlights

● Lipella Pharmaceuticals' chief executive publicly addressed stockholders in a letter following the company's delisting from the Nasdaq Capital Market, confirmed in a press release dated June 25, 2025.

● The delisting followed earlier positive topline Phase 2a results for lead candidate LP-310 in oral lichen planus, reported in February 2025.

● Additional positive data from a second cohort of the same Phase 2a study was reported in the months that followed, with the company signaling it was advancing toward a Phase 2b trial.

● A Nasdaq delisting tied to listing-standards non-compliance does not necessarily indicate any failure of the underlying scientific programme.

Lipella Pharmaceuticals' (OTC:LIPO) chief executive publicly addressed stockholders directly after the clinical-stage biopharmaceutical company was Delisted from the Nasdaq Capital Market, using a public letter to explain the delisting and to outline the company's plans going forward even as its lead clinical programme continued to generate encouraging trial data. The company confirmed the Nasdaq delisting and the accompanying CEO letter in a press release dated June 25, 2025.

Business Overview

Lipella Pharmaceuticals develops treatments for diseases affecting the bladder and oral cavity, with its lead candidate, LP-310, an oral rinse formulation of the immunosuppressant tacrolimus being studied for oral lichen planus, a chronic inflammatory condition that causes painful lesions inside the mouth.

The company positions itself within the specialist and rare-disease segment of the health technology sector, pursuing indications that larger pharmaceutical companies have generally not prioritized. Oral lichen planus currently has no therapy specifically approved to treat it in most major markets, meaning physicians and patients typically rely on treatments developed for other conditions and used off-label, a gap that gives a purpose-built, successfully approved therapy a meaningful commercial opportunity if LP-310 ultimately clears the remaining stages of clinical development.

Latest Development

The single most recent verified development is the Nasdaq delisting and the CEO's letter to stockholders, which followed earlier positive topline Phase 2a results for LP-310 in oral lichen planus that the company had reported in February 2025. Additional positive data from a second cohort of that same Phase 2a study was then reported in the months that followed, with the company at the time signaling it was advancing toward a Phase 2b trial and continued regulatory engagement, even as its Nasdaq listing status came under separate compliance pressure.

Financial and Sector Context

A Nasdaq delisting driven by listing-standards non-compliance, most commonly tied to minimum bid price or minimum Market Value requirements, does not necessarily by itself indicate any failure of the underlying scientific programme, and Lipella's positive clinical trial data reported around the same period usefully illustrates that a company's stock-exchange listing status and its underlying clinical programme's scientific progress can diverge quite meaningfully from one another. The near-zero share price and thin market Capitalization are nonetheless consistent with a company that has lost much of the visibility and trading Liquidity that a Nasdaq listing typically provides.

Risks

The reduced access to Capital Markets financing that typically follows a Nasdaq delisting can be particularly consequential for a small clinical-stage biotechnology company that still needs substantial further funding to advance LP-310 through its Phase 2b trials, further regulatory engagement and, eventually, a potential formal approval filing. There is also the standard clinical-development risk inherent in any drug candidate that has not yet completed pivotal trials, meaning positive Phase 2a data provides no conclusive guarantee of eventual regulatory approval or commercial success.

Clinical Progress Continues Despite Listing Loss

Readers should watch for further updates on LP-310's progression toward a Phase 2b trial and continued regulatory engagement, any subsequent financing announcements addressing the company's ongoing capital needs following its Nasdaq delisting, and whether Lipella outlines a credible path back toward a major exchange listing.